Loading
A phase 2 trial of FOLFIRI, Fluorouracil, FLOT in colorectal cancer, run by AstraZeneca, now recruiting.
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer is a phase 2 interventional study registered as NCT06792695 by AstraZeneca, with 80 participants planned, started 2025-03-12 and due to reach its primary completion in 2027-06-30. Interventions recorded: Volrustomig, FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan), Bevacizumab. Conditions listed: Metastatic Colorectal Cancer. No results are recorded here; the registry entry is the source.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), AstraZeneca.
Shares FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Bevacizumab, Colorectal cancer.
Shares FLOT (5-FU, leucovorin, oxaliplatin, docetaxel), FOLFIRI (5-FU, leucovorin, irinotecan), Fluorouracil (5-FU), Colorectal cancer.